mRNA-1345

BIOLOGICAL15 trials

Conditions

Acute lower respiratory infectionCytomegalovirusHuman MetapneumovirusInfluenzaRSVRespiratory Syncytial VirusRespiratory syncytial virusSARS-CoV-2

Phase 1

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

CompletedNCT04528719

ModernaTX, Inc.Respiratory Syncytial Virus

Start: 2020-09-30End: 2024-07-18Updated: 2024-08-07

A Study of Modified mRNA Vaccines in Healthy Adults

CompletedNCT05397223

ModernaTX, Inc.Cytomegalovirus, Respiratory Syncytial Virus, SARS-CoV-2 +1

Start: 2022-05-24End: 2026-02-27Updated: 2026-03-12

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

CompletedNCT05585632

ModernaTX, Inc.Influenza, RSV, SARS-CoV-2

Start: 2022-10-14End: 2024-02-28Updated: 2024-03-08

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Active, not recruitingNCT05743881

ModernaTX, Inc.Human Metapneumovirus, Respiratory Syncytial Virus

Start: 2023-02-15End: 2026-09-30Updated: 2025-11-24

A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 months to < 24 months

CompletedCTIS2022-502022-41-00

Moderna Inc.Acute lower respiratory infection

Start: 2024-05-28End: 2024-12-18Target: 248Updated: 2024-09-24

Phase 2

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

CompletedNCT05127434

ModernaTX, Inc.Respiratory Syncytial Virus

Start: 2021-11-17End: 2025-07-28Updated: 2025-08-19

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

CompletedNCT05606965

ModernaTX, Inc.Influenza

Start: 2022-11-02End: 2025-11-13Updated: 2025-11-24

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

CompletedNCT06097299

ModernaTX, Inc.Respiratory Syncytial Virus

Start: 2023-10-24End: 2025-06-27Updated: 2025-07-10

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

Active, not recruitingNCT06143046

ModernaTX, Inc.Respiratory Syncytial Virus

Start: 2023-11-15End: 2026-05-27Updated: 2026-02-05

A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Pregnant Women, and Safety, and Immunogenicity in Infants Born to Vaccinated Mothers.

CompletedCTIS2023-505359-37-00

Moderna Inc.Respiratory syncytial virus

Start: 2024-09-03End: 2025-04-30Target: 25Updated: 2025-02-20

Phase 3

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

CompletedNCT05330975

ModernaTX, Inc.Respiratory Syncytial Virus

Start: 2022-04-01End: 2024-11-08Updated: 2025-12-30

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

CompletedNCT06060457

ModernaTX, Inc.Respiratory Syncytial Virus

Start: 2023-09-25End: 2024-06-07Updated: 2025-07-30

A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

Active, not recruitingNCT06067230

ModernaTX, Inc.Respiratory Syncytial Virus

Start: 2023-10-06End: 2026-07-30Updated: 2025-08-08

A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

Active, not recruitingNCT07117487

ModernaTX, Inc.Respiratory Syncytial Virus

Start: 2025-08-05End: 2026-04-15Updated: 2026-01-30

Unknown Phase

Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

CompletedNCT05572658

ModernaTX, Inc.Respiratory Syncytial Virus

Start: 2022-09-15End: 2023-09-30Updated: 2025-01-24

2026-02-18

An mRNA influenza vaccine induces immunity comparable to an adjuvanted vaccine in a randomized trial.

2026-01-14

223. Safety, Tolerability, and Immunogenicity of the mRNA-1345 RSV Vaccine in Solid Organ Transplant Recipients Aged ≥18 Years

Open Forum Infectious Diseases2026-01-01

P-1454. mRNA-Based Respiratory Syncytial Virus Vaccine mRNA-1345 Induces Robust, Polyfunctional, and Durable CD4+ and CD8+ T Cell Responses with Similar Features in Adults Across Age Groups

Open Forum Infectious Diseases2026-01-01

P-1447. T-Cell Responses Following Two Doses of mRNA-1345 in Adult Solid Organ Transplant Recipients

Open Forum Infectious Diseases2026-01-01

P-1453. Characterization of longitudinal humoral and cellular immunogenicity following 2 or 3 doses of an mRNA-based cytomegalovirus vaccine in healthy adults

Open Forum Infectious Diseases2026-01-01

P-1446. Durable RSV-Specific CD4⁺ T-Cell Responses Following mRNA-1345 Vaccination in Adults at Increased Risk of Lower Respiratory Tract Disease Due to RSV

Open Forum Infectious Diseases2026-01-01

P-1452. A Seasonal Influenza Hemagglutinin mRNA-Based Vaccine Induces Humoral and Cellular Immunity Comparable to an Adjuvanted Inactivated Influenza Virus Vaccine

Open Forum Infectious Diseases2026-01-01

mRNA-1010 influenza vaccine elicits distinct and enhanced humoral immunity compared to adjuvanted inactivated vaccines.

2025-12-15

An mRNA-based cytomegalovirus vaccine induces robust T-cell immune responses in cytomegalovirus-seropositive adults who have undergone allogeneic hematopoietic cell transplantation

Blood2025-11-03

Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years

Clinical Infectious Diseases2025-09-242 citations

Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12–59 months

Human Vaccines & Immunotherapeutics2025-09-153 citations

Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial

Nature Communications2025-07-037 citations

Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18–59 Years

Clinical Infectious Diseases2025-06-042 citations

Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical study

Frontiers in Immunology2025-04-105 citations

P-97. Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an Investigational Vaccine Against RSV, Given at 12 Months Following a Primary Dose in Adults Aged ≥ 50 Years

Open Forum Infectious Diseases2025-01-29

Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.

2024-11-2512 citations

Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trial.

2024-09-093 citations

Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults.

2024-09-0140 citations

Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial.

2024-09-0121 citations

5 more papers not shown

mRNA-1345

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Unknown Phase

Related Papers